Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [31] Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
    Pi-Sunyer, F. Xavier
    Schweizer, Anja
    Mills, David
    Dejager, Sylvie
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 132 - 138
  • [32] A comparison of the effect of pioglitazone and gliclazide monotherapy onILipid profiles in drug-naive patients with Type II diabetes.
    Robinson, P
    Lee, CEF
    Edwards, GC
    Urquhart, R
    Tan, MH
    DIABETOLOGIA, 2003, 46 : A291 - A291
  • [33] Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
    Shimoda, Seiya
    Iwashita, Shinsuke
    Sekigami, Taiji
    Furukawa, Noboru
    Matsuo, Yasuto
    Ichimori, Shinji
    Goto, Rieko
    Maeda, Takako
    Watanabe, Eiichiro
    Kondo, Tatsuya
    Matsumura, Takeshi
    Motoshima, Hiroyuki
    Nishida, Kenro
    Araki, Eiichi
    JOURNAL OF DIABETES INVESTIGATION, 2014, 5 (03) : 320 - 326
  • [34] Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus
    Cho, Young Min
    Koo, Bo Kyung
    Son, Ho Young
    Lee, KwangWoo
    Son, Hyun Shik
    Choi, Dong Seop
    Kim, Bo Wan
    Kim, Yong Ki
    Lee, Moon Kyu
    Lee, Hyun Chul
    Min, Kyung Wan
    Chung, Min Young
    Baek, Hong Sun
    Kim, Youngkun
    Yoo, Hyung Joon
    Park, Kyong Soo
    Lee, Hong Kyu
    JOURNAL OF DIABETES INVESTIGATION, 2010, 1 (04): : 143 - 148
  • [35] Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
    Kubota, Akira
    Maeda, Hajime
    Kanamori, Akira
    Matoba, Kiyokazu
    Jin, Yasuyuki
    Minagawa, Fuyuki
    Obana, Mitsuo
    Iemitsu, Kotaro
    Ito, Shogo
    Amamiya, Hikaru
    Kaneshiro, Mizuki
    Takai, Masahiko
    Kaneshige, Hideaki
    Hoshino, Kazuhiko
    Ishikawa, Masashi
    Minami, Nobuaki
    Takuma, Tetsuro
    Sasai, Nobuo
    Aoyagi, Sachio
    Kawata, Takehiro
    Mokubo, Atsuko
    Takeda, Hiroshi
    Honda, Shin
    Machimura, Hideo
    Motomiya, Tetsuya
    Waseda, Manabu
    Naka, Yoshikazu
    Tanaka, Yasushi
    Terauchi, Yasuo
    Matsuba, Ikuro
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (06) : 503 - 509
  • [36] Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
    Scherbaum, W. A.
    Schweizer, A.
    Mari, A.
    Nilsson, P. M.
    Lalanne, G.
    Jauffret, S.
    Foley, J. E.
    DIABETES OBESITY & METABOLISM, 2008, 10 (08): : 675 - 682
  • [37] Exploring time in tight range targets (TITR) in drug-naive Japanese individuals with type 2 diabetes
    Ishiguro, Mizuki
    Ando, Kiyotaka
    Nishimura, Rimei
    ACTA DIABETOLOGICA, 2024, 61 (07) : 933 - 936
  • [38] Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
    Tajima, Naoko
    Kadowaki, Takashi
    Okamoto, Taro
    Sato, Asako
    Okuyama, Kotoba
    Minamide, Toshiomi
    Ferreira, Juan Camilo Arjona
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (06) : 595 - 604
  • [39] Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial
    Fujimoto, Kanta
    Shibayama, Yui
    Yamaguchi, Eriko
    Honjo, Sachiko
    Hamasaki, Akihiro
    Hamamoto, Yoshiyuki
    JOURNAL OF DIABETES, 2018, 10 (08) : 675 - 682
  • [40] Effect of exenatide versus insulin on inflammation in newly diagnosed and drug-naive Chinese type 2 diabetic patients
    Yan, Jinhua
    Xu, Fen
    Deng, Hongrong
    Xu, Wen
    Liang, Hua
    Yao, Bin
    Weng, Jianping
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 : 53 - 53